title: A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells.
abstract: BACKGROUND
  In patients with chronic myelocytic leukemia (CML), the breakpoint cluster region and fusion between the BCR and the c-ABL genes (BCR-ABL) oncogen product is a potential tumor-specific antigen. Previous studies have shown that T cells specific for the junctional region peptides of the BCR-ABL oncoprotein can be detected in healthy individuals as well as in patients with CML in chronic phase. We assessed whether BCR-ABL- specific T cells could be found in a patient achieving a complete cytogenetic remission after CD4+ donor lymphocyte infusion.
  
  
  METHODS
  Using dendritic cells pulsed with BCR-ABL breakpoint peptides as antigen-presenting cells, we stimulated patient peripheral blood lymphocytes to isolate peptide-specific T cell clones present at the time of the cytogenetic response. T cell clones were isolated and the cellular specificity of these cells was examined.
  
  
  RESULTS
  A CD3+ CD4+ T cell clone (1F7) that recognizes overlapping p210 junctional peptides presented by HLA-DR molecules was identified and expanded in vitro. Clone 1F7 failed to recognize autologous tumor cells as well as dendritic cells derived from patient CML cells. Clone 1F7 did not inhibit the growth and differentiation of CML precursor cells in a standard colony formation assay. Finally, using a clone-specific probe, 1F7 cells could not be detected in patient peripheral blood at the time of the donor lymphocyte infusion response.
  
  
  CONCLUSIONS
  These results suggest that clone 1F7 was selected in vitro using highly potent peptide pulsed dendritic cells but was not representative of the anti-leukemia immune response in vivo. Based on these findings, CD4+ T cells with BCR-ABL specificity do not appear to be mediators of the anti-leukemia response in vivo after donor lymphocyte infusion.
authors.affiliation: Center for Hematologic Oncology, Dana-Farber Cancer Institute, Department of Medicine, Brigham and Women Hospital, Harvard Medical School, Boston, MA 02115, USA.
authors.forename: E
authors.initials: E
authors.lastname: Zorn
authors.forename: E
authors.initials: E
authors.lastname: Orsini
authors.forename: C J
authors.initials: CJ
authors.lastname: Wu
authors.forename: B
authors.initials: B
authors.lastname: Stein
authors.forename: A
authors.initials: A
authors.lastname: Chillemi
authors.forename: C
authors.initials: C
authors.lastname: Canning
authors.forename: E P
authors.initials: EP
authors.lastname: Alyea
authors.forename: R J
authors.initials: RJ
authors.lastname: Soiffer
authors.forename: J
authors.initials: J
authors.lastname: Ritz
mesh_terms: D000328:Adult; D000595:Amino Acid Sequence; D000938:Antigen-Presenting Cells / Q000276:immunology; D016026:Bone Marrow Transplantation / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D002999:Clone Cells; D003713:Dendritic Cells / Q000276:immunology; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000276:immunology*; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics* / Q000276:immunology*; D017710:Lymphocyte Transfusion; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000276:immunology
chemical_list: D006680:HLA Antigens; D010446:Peptide Fragments; D016044:Fusion Proteins, bcr-abl